DalsnaFinance › IPOs › Generate Biomedicines › IPO
Generate Biomedicines, Inc. completed its initial public offering on NASDAQ on February 27, 2026, pricing at $16.00 a share.
| Ticker | GENB |
|---|---|
| Exchange | NASDAQ |
| Status | Completed |
| Listing date | February 27, 2026 |
| Offering price | $16.00 |
| Shares offered | 25,000,000 |
| Total raised | $400M |
Generate Biomedicines, Inc. sold 25,000,000 shares at $16.00 each on NASDAQ. Multiplied out, that is $400 million in gross proceeds, the figure before underwriting discounts and offering expenses, and it agrees with the $400 million total recorded for the deal.
Measured by money raised, Generate Biomedicines, Inc. was tied for the 63rd largest (level with 2 other deals) of 473 completed IPOs with a recorded deal size that this site tracks since October 5, 2024. The median deal in the same window raised $200 million, so this one was about 2.0 times the typical size.
Among the 342 listings on NASDAQ alone, it is tied for the 32nd largest (level with 1 other listing).
February 2026 saw 41 completed IPOs in the site's data; by amount raised, Generate Biomedicines, Inc. was the 3rd largest of the 41 deals with a recorded size.
Its $16.00 offer price was tied for the 109th highest (level with 11 other listings) of the 479 listings in the window with a recorded price. A share price on its own says nothing about a company's value; it depends on how many shares exist.
Generate Biomedicines, Inc. — quote, profile and latest news →
Source: SEC EDGAR filings for Generate Biomedicines, Inc.. This page is general information, not investment advice.